Avastin boosts vitrectomy success rates

Article

Avastin (bevacizumab; Genentech) increases the ease of vitrectomy in severe proliferative diabetic retinopathy (PDR), according to a study published in the July issue of Clinical and Experimental Ophthalmology.

Avastin (bevacizumab; Genentech) increases the ease of vitrectomy in severe proliferative diabetic retinopathy (PDR), according to a study published in the July issue of Clinical and Experimental Ophthalmology.

Jonathan Yeoh of the Vitreoretinal Unit and the Royal Victorian Eye and Ear Hospital in Melbourne, Australia and colleagues gave a single injection of Avastin to 16 study subjects (18 eyes) with severe PDR who were about to undergo vitrectomy to treat either tractional retinal detachment or vitreous haemorrhage.

Three months postoperatively, visual acuity (VA) had remained the same or improved over baseline in 11 eyes; by the six month follow-up point, VA had improved over baseline in 14 eyes, and remained the same in one eye. Of the seven rebleeds that occurred after surgery, six required surgical washout.

The researchers therefore concluded that Avastin facilitates vitrectomy success in PDR subjects, and noted that this technique is particularly useful when neovascularization is still active and short duration traction detachments are being treated.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.